Affibody Medical Investor Relations

Data demonstrating pre-clinical efficacy and safety of Affibody’s radio-therapeutic anti-HER2 agent ABY-271 presented at EANM annual congress

News

October 20, 2024

Affibody AB (“Affibody”) announces presentation of data from IND enabling preclinical studies with the radiotherapeutic agent 177Lu-ABY-271 for treatment of HER2 expressing metastatic disease. The data will be presented today at the Annual Congress of the European Association of Nuclear Medicine.

The data will be presented in the radiopharmaceuticals sciences and translational therapy session by investigator Yongsheng Liu in the Professor Tolmachev group, Uppsala University. Strong therapeutic effect of HER2 targeted 177Lu is demonstrated with significantly longer survival for the treatment group as compared to trastuzumab standard of care treatment.

“These data suggest that our drug candidate could reach meaningful levels of drug in tumors of patients with metastatic disease” says Fredrik Frejd, CSO, Affibody AB. “The drug is in late IND enabling development, and we anticipate early clinical data by mid next year”, he continues.

The presentation details are as follows:
Title: A Novel 177Lu-labelled Affibody Molecule with Deimmunized ABD: Enhanced Biodistribution Profile and Anti-tumour Efficacy
Presentation Number: OP-085    
Session Number: 304
Session Title: M2M Track – TROP
Session: Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: Antibodies & Co.
Session Timing & Location: October 20, 2024; 09:45 – 11:15a.m. CET, Hall X1–X4
Presentation Timing: October 20, 2024; 10.15-10.25 a.m. CET

Additional information about EANM 2024 is available at: https://eanm24.eanm.org/.